CervoMed Inc.
CRVO•NASDAQ•Healthcare•Biotechnology

About CervoMed

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. It is being evaluated in a Phase 2b study in patients with DLB. The company develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOJohn Alam
Founded2001
Employees15
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitewww.cervomed.com
Phone617 744 4400
Address
20 Park Plaza, Suite 424 Boston, Massachusetts 02116 United States

Corporate Identifiers

CIK0001053691
CUSIP15713L109
ISINUS15713L1098
EIN30-0645032
SIC2834

Leadership Team & Key Executives

Dr. John J. Alam M.D.
Co-Founder, Chief Executive Officer, President and Director
Dr. Sylvie L. Gregoire Pharm.D.
Co-Founder and Director
William Robert Elder J.D.
Chief Financial Officer, General Counsel and Corporate Secretary
Dr. Marinus Verwijs Ph.D.
Executive Vice President of Technical Operations
Kelly Blackburn M.H.A.
Executive Vice President of Clinical Development
Dr. Mark A. De Rosch Ph.D.
Executive Vice President of Regulatory, Government Affairs and Program Management
Dr. Claudia Ordonez M.D.
Senior Vice President of Medical Science
Dr. Matthew Winton Ph.D.
Chief Commercial and Business Officer